Scopus Biopharma, Inc. (SCPS)
| Market Cap | 5.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.90M |
| Shares Out | 21.09M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,667 |
| Open | 0.243 |
| Previous Close | 0.244 |
| Day's Range | 0.231 - 0.248 |
| 52-Week Range | 0.210 - 4.280 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.24 (+4,955.8%) |
| Earnings Date | n/a |
About SCPS
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhi... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SCPS stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 4,955.76% from the latest price.
News
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies S...
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology
Scopus BioPharma Provides Update Following Annual Meeting of Stockholders
Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees
DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC.
NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.00...
Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the Company
Latest Legal Claims by Laster Actually Call into Question his Stock Ownership
Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company's Director Nominees on the WHITE P...
Company's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies
Dr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual M...
NEW YORK and JERUSALEM, Dec. 6, 2021 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with the other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $...
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...
Scopus BioPharma to Present at the LD Micro Main Event
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct...
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Ann...
Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice
Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the ...
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...
Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of ...
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signifi...
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Ther...
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 In...
New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Bo...
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scie...
Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope Natio...
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Pr...
What Is Happening With Scopus BioPharma Stock On Thursday?
Scopus BioPharma Inc (NASDAQ: SCPS) has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune. Related Content: Scopus Bio...
Scopus BioPharma Launches Duet Therapeutics
Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...
Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune
Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company's 2021 Annual Meeting of Stockholders (“2021 Ann...